Epoprostenol Injection, Powder, Lyophilized, For Solution
NDC 68083-707
Product Information
Epoprostenol is a ANDA-approved product labeled by Gland Pharma Limited. This medication is typically used as a prostacycline vasodilator [epc]. It is supplied as a injection, powder, lyophilized, for solution for intravenous administration. This product entry covers the primary NDC 68083-707 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 68083-707?
What are the uses of this product?
What are Active Ingredients of this product?
- EPOPROSTENOL .5 mg/10mL - A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- EPOPROSTENOL (UNII: DCR9Z582X0)
- EPOPROSTENOL (UNII: DCR9Z582X0) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SUCROSE (UNII: C151H8M554)
- GLYCINE (UNII: TE7660XO1C)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 562501 - epoprostenol 0.5 MG Injection
- RxCUI: 562501 - epoprostenol 0.5 MG (as epoprostenol sodium) Injection
- RxCUI: 562502 - epoprostenol 1.5 MG Injection
- RxCUI: 562502 - epoprostenol 1.5 MG (as epoprostenol sodium) Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.